Treatment of T. cruzi infected human platelet concentrates with aminomethyltrimethyl psoralen (AMT) and ultravioleta (UV-A) light: preliminary results

• Main Authors: Hélio Moraes-Souza, José Orlando Bordin, Leslie Bardossy, Morris A. Blajchman
• Format: Article in Journal/Newspaper
• Language: English
• Published: Sociedade Brasileira de Medicina Tropical (SBMT) 1996
• Subjects: Doença de Chagas transfusional; Quimioprofilaxia; Tratamento fotodinâmico; Luz ultravioleta e doença de Chagas; Transfusão de sangue; Transfusion-associated Chagas' disease; Phtodynamic treatment; UV-A and Chagas' disease; Chemoprophylaxis; Blood transfusion; Arctic medicine. Tropical medicine; RC955-962; Arctic; The ''Y''
• Online Access: https://doaj.org/article/4c0a8fd07608424589ca46c62a63a792

The present measures adopted to prevent transfusion-associated Chagas' disease include screening of blood donors. and/or the inactivation of T. cruzi in collected blood using gentian violet (GV) as a trypanocidal agent. In this study, we investigated the efficacy of the combined use of AMT and UV-A in inactirating T. cruzi in infected human platelet cuncentrates. Human platelet concentrates were infected with T. cruzi (2x10/ml) of the Y strain transfered to PL 269 (Fenwal Laboratories) containers and treated with GV (250řg,/ml). and ascorbic acid (1 mg/ml); GV. ascorbic acid and UV-A; GV and UV-A; AMT (40/tG/ml) and ascorbic acid; AMT, ascorbic acid and UV-A; AMT and UV-A; UV-A alone; and untreated (control). All UV-A treated platelet concentrates were exposed to UV-A doses of 24, 92, 184, 276, 368 and 644 kj/m². and the microscopical research of active T. cruzi was performed, using the microhematocrit technique, 1, 6 and 24 hours after each treatment. A high number of active forms of T. cruzi was observed in all condictions, except when GV was used as the trypanocidal agent, providing evidence of the failure of AMT and UV-A in inactivating T cruzi in infected human platelet concentrates. As medidas adotadas atualmente para prevenir a doença de Chagas transfusional incluem a seleção dos doadores de sangue e/ou a inativação do T. cruzi no sangue coletado através do uso da violeta de genciana (VG) como agente tripanosomicida. Neste estudo, nós investigamos a eficácia do uso combinado do AMTe da UV-A para a neutralização do T. cruzi em concentrados de plaquetas humanas infectados. Os concentrados de plaquetas infectados com cepa Y de T. cruzi (2x10/ml) foram transferidos para recipientes PL. 269 (Fenwal Laboratories) e tratados com VG (250/ml) e ácido ascórbico (1mg/ml) VG. ácido ascórbico e UV-A; GV e UV-A; AMT (40 G/ml) e ácido ascórbico; AMT, ácido ascórbico e UV-A; AMT e UV-A; somente UV-A; e não tratado (controle). Todos os concentrados de plaquetas foram expostos a doses de 24, 92, 184, 276, 368 e 644 kJ/m² ...